KOD Stock Analysis: Kodiak Sciences Inc.
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macula
- Latest close
- $89.92
- 20-day change
- +138.39%
- Trend state
- LEAN BULL
- Classification
- Healthcare · Biotechnology
Market context
Kodiak Sciences Inc. moved +138.39% over the latest 20-session window. BullRecon currently classifies the broader setup as LEAN BULL.
Latest report
The latest cached company filing period (FY2025 · -$230M net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Health is currently the strongest dimension at 4.3/6, while Value is the lowest at 0.5/6. Scores are comparative research signals, not forecasts.